Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Salgado, R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Eynden, F. Baehner, F. Penault-Llorca, E. Perez, E. Thompson, W. Symmans, A. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D. Rimm, K. Allison, J. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Annals of oncology : official journal of the European Society for Medical Oncology, 26 2
Johnathan Watkins, S. Irshad, A. Grigoriadis, A. Tutt (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersBreast Cancer Research : BCR, 16
A. Gucalp, S. Tolaney, S. Isakoff, J. Ingle, Minetta Liu, L. Carey, K. Blackwell, H. Rugo, L. Nabell, A. Forero, V. Stearns, A. Doane, M. Danso, M. Moynahan, L. Momen, Joseph Gonzalez, A. Akhtar, D. Giri, S. Patil, K. Feigin, C. Hudis, T. Traina (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast CancerClinical Cancer Research, 19
G. Minckwitz, E. Hahnen, P. Fasching, J. Hauke, A. Schneeweiss, C. Salat, M. Rezai, J. Blohmer, D. Zahm, C. Jackisch, B. Gerber, P. Klare, S. Kümmel, H. Eidtmann, S. Paepke, V. Nekljudova, S. Loibl, M. Untch, R. Schmutzler, Gbg, Ago-B groups (2014)
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.Journal of Clinical Oncology, 32
T. Chan, J. Wolchok, A. Snyder (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.The New England journal of medicine, 373 20
F. André, C. Zielinski (2012)
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 6
J. Fricker (2009)
San Antonio Breast Cancer Symposium.The Lancet. Oncology, 10 1
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
G. Emons, G. Gorchev, P. Harter, P. Wimberger, A. Stähle, L. Hanker, F. Hilpert, M. Beckmann, P. Dall, C. Gründker, H. Sindermann, J. Sehouli (2014)
Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH ReceptorsInternational Journal of Gynecological Cancer, 24
S. Seitz, S. Buchholz, A. Schally, F. Weber, M. Klinkhammer-Schalke, E. Inwald, R. Perez, F. Rick, L. Szalontay, F. Hohla, S. Segerer, C. Kwok, O. Ortmann, J. Engel (2014)
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125BMC Cancer, 14
S. Loi, N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Eenoo, G. Rouas, P. Francis, J. Crown, E. Hitre, E. Azambuja, E. Quinaux, A. Leo, S. Michiels, M. Piccart, C. Sotiriou (2013)
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 7
G. Minckwitz, K. Timms, M. Untch, E. Elkin, P. Fasching, A. Schneeweiss, C. Salat, M. Rezai, J. Blohmer, D. Zahm, C. Jackisch, B. Gerber, P. Klare, S. Kümmel, H. Eidtmann, S. Paepke, J. Reid, V. Nekljudova, A. Hartman, S. Loibl (2015)
Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.Journal of Clinical Oncology, 33
T. Helleday, E. Petermann, Cecilia Lundin, B. Hodgson, Ricky Sharma (2008)
DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 8
C. Criscitiello, H. Azim, P. Schouten, S. Linn, C. Sotiriou (2012)
Understanding the biology of triple-negative breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 6
K. Baumann, L. Kiesel, M. Kaufmann, G. Bastert, B. Runnebaum (2004)
Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parametersBreast Cancer Research and Treatment, 25
M. Burstein, A. Tsimelzon, Graham Poage, K. Covington, A. Contreras, S. Fuqua, Michelle Savage, K. Osborne, S. Hilsenbeck, Jenny Chang, G. Mills, C. Lau, P. Brown (2014)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research, 21
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
Z. Mohammed, J. Going, J. Edwards, B. Elsberger, J. Doughty, D. McMillan, D. McMillan (2012)
The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancerBritish Journal of Cancer, 107
J. Thigpen (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerYearbook of Medicine, 2011
(2010)
Poly(ADP-Ribose) polymerase inhibition: Btargeted^ therapy for triple-negative breast cancer
L. Gonzalez, M. Corte, J. Vázquez, S. Junquera, R. Sánchez, A. Alvarez, J. Rodríguez, M. Lamelas, F. Vizoso (2008)
Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitorsBMC Cancer, 8
J. Engel (2015)
GHRH-antagonists in TNBCOncotarget, 6
C. Anders, E. Winer, J. Ford, R. Dent, D. Silver, G. Sledge, L. Carey (2010)
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast CancerClinical Cancer Research, 16
O. Metzger-Filho, Zhuoxin Sun, G. Viale, K. Price, D. Crivellari, R. Snyder, R. Gelber, M. Castiglione‐Gertsch, A. Coates, A. Goldhirsch, F. Cardoso (2013)
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 25
A. Sonnenblick, E. Azambuja, H. Azim, M. Piccart (2015)
An update on PARP inhibitors—moving to the adjuvant settingNature Reviews Clinical Oncology, 12
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
Qin Yu, Y. Niu, N. Liu, J. Zhang, Tieju Liu, R. Zhang, Shu-ling Wang, X. Ding, X. Xiao (2011)
Expression of androgen receptor in breast cancer and its significance as a prognostic factor.Annals of oncology : official journal of the European Society for Medical Oncology, 22 6
G. Minckwitz, M. Untch, J. Blohmer, S. Costa, H. Eidtmann, P. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober, C. Jackisch, M. Kaufmann, G. Konecny, C. Denkert, V. Nekljudova, K. Mehta, S. Loibl (2012)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
S. Alkhayyat, Muhammad Khan, Tauseef Ahmad, Haroon, Huma Tariq, M. Baig (2022)
A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genesMedicine, 101
P. Fong, T. Yap, D. Boss, C. Carden, M. Mergui-Roelvink, C. Gourley, J. Grève, J. Lubiński, S. Shanley, C. Messiou, R. A’Hern, A. Tutt, A. Ashworth, J. Stone, J. Carmichael, J. Schellens, J. Bono, S. Kaye (2010)
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 15
Joshua McMichael, L. Fulton, D. Dooling, Li Ding, R. Elaine, Mardis, R. Wilson, Miruna, Balasundaram, R. Carlsen, Candace Carter, Andy, M Chu, E. Chuah, Noreen Dhalla, Ranabir, Guin, Carrie Hirst, M. Hirst, R. Holt, D. Lee, Michael, Mayo, Richard Moore, A. Mungall, E. Pleasance, A. GordonRobertson, J. Schein, A. Shafiei, Payal Sipahimalani, Jared Slobodan, Yongjun Zhao, I. Birol, Steven Jones, R. Onofrio, S. Carter, S. Schumacher, B. Tabak, Bryan Hernandez, R. Beroukhim, W. Winckler, S. Gabriel, A. Prat, Grace Silva, Jerry Usary, Douglas Voet, N. Gehlenborg, Mike Lawrence, Lihua, Zou, Pei Lin, R. Jing, JuokCho, Raktim, Sinha, R. Park, Marc-Danie Nazaire, James Robinson, Helga, Thorvaldsdottir, J. Mesirov, Peter Park, L. Chin, R. Kreisberg, A. Jacobsen, Rileen Sinha, B. Reva, R. Shen, B. Taylor, Tod Casasent, A. Unruh, Joshua Stuart, Jingchun Zhu, Chris Szeto, G. Scott, C. Yau, Evan, O. Paull, Daniel Carlin, Artem Sokolov, J. Thusberg, S. Mooney, Jay Bowen, N. Ramirez, D. Aaron, Black, R. Pyatt, P. White, E. Zmuda, J. Frick, M. Tara, Lichtenberg, Robin Brookens, Myra George, Mark Gerken, A. Hollie, Harper, K. Leraas, Teresa Tabler (2013)
Comprehensive molecular portraits of human breast tumoursYearbook of Pathology and Laboratory Medicine, 2013
(2015)
a metastatic mediator and emerging therapeutic target in cancer
S. Kakar, W. Grizzle, J. Neill (1994)
The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitaryMolecular and Cellular Endocrinology, 106
(2006)
CR 011 , a fully human monoclonal antibody - auristatin E conjugate , for the treatment of melano
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
H. Masuda, K. Baggerly, Ying Wang, Ya Zhang, A. González-Angulo, F. Meric-Bernstam, V. Valero, B. Lehmann, J. Pietenpol, G. Hortobagyi, W. Symmans, N. Ueno (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular SubtypesClinical Cancer Research, 19
M. Ono, H. Tsuda, C. Shimizu, Sohei Yamamoto, T. Shibata, H. Yamamoto, T. Hirata, K. Yonemori, M. Ando, K. Tamura, N. Katsumata, T. Kinoshita, Y. Takiguchi, H. Tanzawa, Y. Fujiwara (2012)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Research and Treatment, 132
A. Tutt, P. Ellis, L. Kilburn, Cheryl Gilett, S. Pinder, J. Abraham, S. Barrett, P. Barrett-Lee, S. Chan, M. Cheang, M. Dowsett, Lisa Fox, P. Gazinska, A. Grigoriadis, A. Gutin, C. Harper-wynne, M. Hatton, S. Kernaghan, J. Lanchbury, J. Morden, J. Owen, J. Parikh, P. Parker, N. Rahman, R. Roylance, A. Shaw, I. Smith, Roxanna Thompson, K. Timms, H. Tovey, A. Wardley, G. Wilson, M. Harries, J. Bliss (2015)
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)Cancer Research, 75
C. Denkert, S. Loibl, A. Noske, M. Roller, B. Müller, M. Komor, J. Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch, C. Törne, W. Weichert, K. Engels, C. Solbach, I. Schrader, M. Dietel, G. Minckwitz (2010)
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
H. Bryant, N. Schultz, H. Thomas, Kayan Parker, Dan Flower, Elena Lopez, S. Kyle, M. Meuth, N. Curtin, T. Helleday (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 447
Z. Fadoukhair, D. Zardavas, M. Chad, T. Goulioti, P. Aftimos, M. Piccart (2016)
Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsOncogene, 35
F. Zagouri, P. Liakou, R. Bartsch, F. Peccatori, A. Tsigginou, C. Dimitrakakis, G. Zografos, M. Dimopoulos, H. Azim (2015)
Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.Breast, 24 4
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
I. Gingras, H. Azim, M. Ignatiadis, C. Sotiriou (2015)
Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.Clinical advances in hematology & oncology : H&O, 13 6
A. Rose, Andrée-Anne Grosset, Zhifeng Dong, C. Russo, Patricia MacDonald, N. Bertos, Y. St-Pierre, R. Simantov, M. Hallett, Morag Park, L. Gaboury, P. Siegel (2010)
Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast CancerClinical Cancer Research, 16
O. Metzger-Filho, A. Tutt, E. Azambuja, K. Saini, G. Viale, S. Loi, I. Bradbury, J. Bliss, H. Azim, P. Ellis, A. Leo, J. Baselga, C. Sotiriou, M. Piccart-Gebhart (2012)
Dissecting the heterogeneity of triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
R. Dent, M. Trudeau, K. Pritchard, W. Hanna, H. Kahn, C. Sawka, L. Lickley, E. Rawlinson, P. Sun, S. Narod (2007)
Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 13
C. Kwok, Oliver Treeck, Stefan Buchholz, S. Seitz, O. Ortmann, J. Engel (2015)
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)Targeted Oncology, 10
J. O’Shaughnessy, L. Schwartzberg, M. Danso, K. Miller, H. Rugo, M. Neubauer, N. Robert, B. Hellerstedt, M. Saleh, P. Richards, J. Specht, D. Yardley, R. Carlson, R. Finn, Eric Charpentier, I. García-Ribas, E. Winer (2014)
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 34
J. Bendell, M. Saleh, A. Rose, P. Siegel, L. Hart, S. Sirpal, Suzanne Jones, Jennifer Green, E. Crowley, R. Simantov, T. Keler, T. Davis, L. Vahdat (2014)
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 32
G Emons, G Gorchev, P Harter (2014)
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)Int J Gynecol Cancer, 24
H. Moore, J. Unger, K. Phillips, F. Boyle, E. Hitre, D. Porter, P. Francis, L. Goldstein, H. Gómez, C. Vallejos, A. Partridge, S. Dakhil, Agustin Garcia, J. Gralow, J. Lombard, J. Forbes, S. Martino, W. Barlow, C. Fabian, L. Minasian, F. Meyskens, R. Gelber, G. Hortobagyi, K. Albain (2015)
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.The New England journal of medicine, 372 10
S. Buchholz, S. Seitz, A. Schally, J. Engel, F. Rick, L. Szalontay, F. Hohla, A. Krishan, A. Papadia, T. Gaiser, G. Brockhoff, O. Ortmann, K. Diedrich, F. Köster (2009)
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.International journal of oncology, 35 4
C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, B. Hennessy, Marjorie Green, M. Cristofanilli, G. Hortobagyi, L. Pusztai (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
E. Wang, E. Jabbour, D. Douer (2015)
Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium.Clinical advances in hematology & oncology : H&O, 13 6 Suppl 7
A. Ghannam, S. Galal, M. Ellity (2016)
Expression of androgen receptors in primary breast cancerAnnals of Oncology, 27
Edward Kim, R. Herbst, I. Wistuba, J. Lee, G. Blumenschein, A. Tsao, D. Stewart, M. Hicks, J. Erasmus, Sanjay Gupta, C. Alden, Suyu Liu, Ximing Tang, F. Khuri, H. Tran, B. Johnson, J. Heymach, L. Mao, F. Fossella, M. Kies, V. Papadimitrakopoulou, Suzanne Davis, S. Lippman, W. Hong (2011)
The BATTLE trial: personalizing therapy for lung cancer.Cancer discovery, 1 1
X. Guan, F. Ma, Ying Fan, Wenjie Zhu, R. Hong, Bing-he Xu (2015)
Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trialsAnti-Cancer Drugs, 26
(2014)
Phase I/II study of the antibodydrug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer
C. Sotiriou, S. Neo, L. McShane, E. Korn, Philip Long, A. Jazaeri, P. Martiat, S. Fox, A. Harris, E. Liu (2003)
Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 100
R. Nanda, L. Chow, E. Dees, R. Berger, Shilpa Gupta, R. Geva, L. Pusztai, M. Dolled-Filhart, K. Emancipator, Edward Gonzalez, J. Houp, K. Pathiraja, V. Karantza, R. Iannone, C. Gause, Johnathan Cheng, L. Buisseret (2015)
Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancerCancer Research, 75
A. Tsimberidou, N. Iskander, D. Hong, J. Wheler, G. Falchook, S. Fu, S. Piha-Paul, A. Naing, F. Janku, R. Luthra, Y. Ye, S. Wen, D. Berry, R. Kurzrock (2012)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center InitiativeClinical Cancer Research, 18
M. Telli, K. Jensen, S. Vinayak, A. Kurian, J. Lipson, P. Flaherty, K. Timms, V. Abkevich, E. Schackmann, I. Wapnir, R. Carlson, Pei-Jen Chang, J. Sparano, Bobbie Head, L. Goldstein, B. Haley, S. Dakhil, J. Reid, A. Hartman, J. Manola, J. Ford (2015)
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
S. Isakoff, E. Mayer, Lei He, T. Traina, L. Carey, K. Krag, H. Rugo, Minetta Liu, V. Stearns, S. Come, K. Timms, A. Hartman, D. Borger, D. Finkelstein, J. Garber, P. Ryan, E. Winer, P. Goss, L. Ellisen (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
F. Vera-Badillo, A. Templeton, P. Gouveia, I. Díaz-Padilla, P. Bedard, M. Al-Mubarak, B. Seruga, I. Tannock, A. Ocaña, E. Amir (2014)
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.Journal of the National Cancer Institute, 106 1
S. Buchholz, S. Seitz, J. Engel, A. Montero, O. Ortmann, R. Perez, N. Block, A. Schally (2012)
Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH)Hormone Molecular Biology and Clinical Investigation, 9
Pam Das, Adeeba Kamarulzaman, Tony Mok, John O'Grady (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialBreast Diseases: A Year Book Quarterly, 22
V. Abkevich, K. Timms, B. Hennessy, J. Potter, M. Carey, L. Meyer, K. Smith-McCune, R. Broaddus, K. Lu, Jian Chen, Thanh Tran, Dominic Williams, D. Iliev, Srikanth Jammulapati, Lisa Fitzgerald, T. Krivak, J. Deloia, A. Gutin, G. Mills, J. Lanchbury (2012)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 107
J. Engel, G. Emons, J. Pinski, A. Schally (2012)
AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptorsExpert Opinion on Investigational Drugs, 21
D. Koboldt, R. Fulton, M. McLellan, Heather Schmidt, Joelle Kalicki-Veizer, Joshua McMichael, L. Fulton, D. Dooling, L. Ding, E. Mardis, R. Wilson, Adrian Ally, M. Balasundaram, Y. Butterfield, R. Carlsen, Candace Carter, Andy Chu, E. Chuah, Hye-Jung Chun, R. Coope, Noreen Dhalla, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, E. Pleasance, A. Robertson, J. Schein, A. Shafiei, Payal Sipahimalani, Jared Slobodan, D. Stoll, Angela Tam, N. Thiessen, R. Varhol, N. Wye, Thomas Zeng, Yongjun Zhao, I. Birol, Steven Jones, M. Marra, A. Cherniack, G. Saksena, R. Onofrio, Nam Pho, S. Carter, S. Schumacher, B. Tabak, Bryan Hernandez, Jeff Gentry, Huy Nguyen, A. Crenshaw, K. Ardlie, R. Beroukhim, W. Winckler, G. Getz, S. Gabriel, M. Meyerson, L. Chin, R. Kucherlapati, K. Hoadley, J. Auman, C. Fan, Yidi Turman, Yan Shi, Ling Li, M. Topal, Xiaping He, H. Chao, A. Prat, Grace Silva, M. Iglesia, Wei Zhao, Jerry Usary, J. Berg, Michael Adams, J. Booker, Junyuan Wu, Anisha Gulabani, T. Bodenheimer, A. Hoyle, J. Simons, Matthew Soloway, Lisle Mose, S. Jefferys, S. Balu, J. Parker, D. Hayes, C. Perou, Simeen Malik, S. Mahurkar, Hui Shen, D. Weisenberger, T. Triche, Phillip Lai, M. Bootwalla, D. Maglinte, B. Berman, D. Berg, S. Baylin, P. Laird, C. Creighton, L. Donehower, M. Noble, Douglas Voet, N. Gehlenborg, D. Cara, Juinhua Zhang, Hailei Zhang, Chang-Jiun Wu, Spring Liu, M. Lawrence, L. Zou, A. Sivachenko, Pei Lin, P. Stojanov, R. Jing, Juok Cho, Raktim Sinha, R. Park, Marc-Danie Nazaire, James Robinson, H. Thorvaldsdóttir, J. Mesirov, P. Park, Sheila Reynolds, R. Kreisberg, Brady Bernard, Ryan Bressler, Timo Erkkilä, Jake Lin, V. Thorsson, Wei Zhang, I. Shmulevich, G. Ciriello, Nils Weinhold, N. Schultz, Jianjiong Gao, E. Cerami, Benjamin Gross, A. Jacobsen, Rileen Sinha, B. Aksoy, Yevgeniy Antipin, B. Reva, R. Shen, B. Taylor, M. Ladanyi, C. Sander, Pavana Anur, P. Spellman, Yiling Lu, Wenbin Liu, R. Verhaak, G. Mills, R. Akbani, Nianxiang Zhang, B. Broom, Tod Casasent, Chris Wakefield, A. Unruh, K. Baggerly, K. Coombes, J. Weinstein, D. Haussler, C. Benz, Joshua Stuart, S. Benz, Jingchun Zhu, C. Szeto, G. Scott, C. Yau, Evan Paull, Daniel Carlin, Christopher Wong, Artem Sokolov, J. Thusberg, S. Mooney, S. Ng, Theodore Goldstein, K. Ellrott, Mia Grifford, C. Wilks, Singer Ma, Brian Craft, Chunhua Yan, Ying Hu, D. Meerzaman, J. Gastier-Foster, Jay Bowen, N. Ramirez, Aaron Black, R. Pyatt, P. White, E. Zmuda, J. Frick, T. Lichtenberg, Robin Brookens, Myra George, M. Gerken, H. Harper, K. Leraas, L. Wise, Teresa Tabler, Cynthia McAllister, T. Barr, Melissa Hart-Kothari, Katherine Tarvin, Charles Saller, G. Sandusky, Colleen Mitchell, M. Iacocca, Jennifer Brown, B. Rabeno, Christine Czerwinski, N. Petrelli, Oleg Dolzhansky, M. Abramov, Olga Voronina, O. Potapova, J. Marks, W. Suchorska, D. Murawa, W. Kycler, Matthew Ibbs, Konstanty Korski, A. Spychała, P. Murawa, Jacek Brzeziński, Hanna Perz, Radoslaw Łaźniak, M. Teresiak, Honorata Tatka, E. Leporowska, M. Bogusz-Czerniewicz, J. Malicki, A. Mackiewicz, M. Wiznerowicz, X. Le, B. Kohl, N. Tien, Richard Thorp, N. Bang, H. Sussman, Bui Phu, R. Hajek, N. Hung, H. Thang, K. Khan, R. Penny, D. Mallery, Erin Curley, C. Shelton, P. Yena, J. Ingle, F. Couch, W. Lingle, T. King, A. González-Angulo, Mary Dyer, Shuying Liu, Xiaolong Meng, Modesto Patangan, F. Waldman, H. Stoppler, W. Rathmell, L. Thorne, Meijuan Huang, L. Boice, Ashley Hill, C. Morrison, Carmelo Gaudioso, W. Bshara, K. Daily, Sophie Egea, M. Pegram, C. Gomez-Fernandez, R. Dhir, R. Bhargava, A. Brufsky, C. Shriver, J. Hooke, J. Campbell, R. Mural, Hai Hu, S. Somiari, C. Larson, B. Deyarmin, L. Kvecher, A. Kovatich, M. Ellis, T. Stricker, K. White, O. Olopade, C. Luo, Y. Chen, R. Bose, Li-Wei Chang, Andrew Beck, T. Pihl, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Zhining Wang, E. Snyder, J. Pontius, Brenda Ayala, M. Backus, Jessica Walton, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, D. Pot, Margi Sheth, John Demchok, K. Shaw, Liming Yang, G. Eley, M. Ferguson, R. Tarnuzzer, J. Zhang, Laura Dillon, K. Buetow, P. Fielding, B. Ozenberger, M. Guyer, H. Sofia, Jacqueline Palchik (2012)
Comprehensive molecular portraits of human breast tumorsNature, 490
A. Rose, F. Pépin, C. Russo, J. Khalil, M. Hallett, P. Siegel (2007)
Osteoactivin Promotes Breast Cancer Metastasis to BoneMolecular Cancer Research, 5
L. Emens, F. Braiteh, P. Cassier, J. Delord, J. Eder, M. Fassò, Yuanyuan Xiao, Yan Wang, L. Molinero, Daniel Chen, I. Krop (2015)
Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)Cancer Research, 75
N. Turner, J. Reis-Filho (2013)
Tackling the Diversity of Triple-Negative Breast CancerClinical Cancer Research, 19
S. Loi, S. Loi, S. Michiels, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart, S. Loibl, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
Leo Niemeier, D. Dabbs, S. Beriwal, Joan Striebel, R. Bhargava (2010)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiationModern Pathology, 23
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
B. Kaufman, R. Shapira-Frommer, R. Schmutzler, M. Audeh, M. Friedlander, J. Balmaña, G. Mitchell, G. Fried, S. Stemmer, A. Hubert, O. Rosengarten, M. Steiner, N. Loman, K. Bowen, A. Fielding, S. Domchek (2015)
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 3
R. Yamaguchi, Maki Tanaka, A. Yano, G. Tse, M. Yamaguchi, Keiko Koura, N. Kanomata, Atsushi Kawaguchi, J. Akiba, Y. Naito, K. Ohshima, H. Yano (2012)
Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer.Human pathology, 43 10
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
A Sonnenblick, E Azambuja, HA Azim, M Piccart (2015)
An update on PARP inhibitors—moving to the adjuvant setting. Nature reviewsClin Oncol, 12
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
J O’Shaughnessy, C Osborne, JE Pippen (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancerN Engl J Med, 364
Carole Beck, I. Robert, B. Reina-San-Martin, V. Schreiber, F. Dantzer (2014)
Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3.Experimental cell research, 329 1
D. Yardley, R. Weaver, M. Melisko, M. Saleh, F. Arena, A. Forero, T. Cigler, A. Stopeck, D. Citrin, I. Oliff, R. Bechhold, R. Loutfi, Agustin Garcia, S. Cruickshank, E. Crowley, Jennifer Green, T. Hawthorne, M. Yellin, T. Davis, L. Vahdat (2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 14
T. Traina, K. Miller, D. Yardley, J. O’Shaughnessy, J. Cortés, A. Awada, C. Kelly, M. Trudeau, P. Schmid, L. Gianni, L. García-Estévez, R. Nanda, F. Ademuyiwa, S. Chan, J. Steinberg, M. Blaney, I. Tudor, H. Uppal, A. Peterson, C. Hudis (2015)
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).Journal of Clinical Oncology, 33
Gordana Marić, A. Rose, M. Annis, P. Siegel (2013)
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancerOncoTargets and therapy, 6
A. Rose, M. Annis, Zhifeng Dong, F. Pépin, M. Hallett, Morag Park, P. Siegel (2010)
ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic PropertiesPLoS ONE, 5
K. Tse, M. Jeffers, V. Pollack, D. McCabe, Melanie Shadish, N. Khramtsov, C. Hackett, S. Shenoy, B. Kuang, F. Boldog, J. Macdougall, L. Rastelli, J. Herrmann, M. Gallo, Gadi Gazit-Bornstein, P. Senter, Damon Meyer, H. Lichenstein, W. Larochelle (2006)
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 12
Triple negative breast cancers (TNBC) are often described as biologically aggressive tumors, with poorer survival compared to other breast cancer subtypes. The fact that TNBC lacks an obvious target like estrogen receptor and HER2 represents a major challenge in the management of these patients. Genomic analyses have revealed that TNBC comprises a diverse group of cancers, which have distinct molecular profiles and different prognosis. These studies also highlighted molecular aberrations that could serve as potential treatment targets. On the other hand, a high percentage of TNBCs express some important surface receptors that have been already exploited in the development of promising targeted therapies, which are currently tested in clinical trials. In this review, we will provide an overview on the molecular diversity of TNBC with special emphasis on the evolving role of some potential biomarkers that may be utilized in the near future.
Current Breast Cancer Reports – Springer Journals
Published: Sep 23, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.